A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).
Inclusion Criteria:
Exclusion Criteria:
• Primary progressive multiple sclerosis
Douglasville, Georgia 30134, United States
Sofia, 1113, Bulgaria
Sittard-Geleen, 6162 BG, Netherlands
Konstancin-Jeziorna, 05-510, Poland
Lódzkie, 90-324, Poland
Mazowieckie, 02-097, Poland
Plewiska, 62-064, Poland
Podlaskie, 15-402, Poland
Poznan, 61-853, Poland
Warminsko-mazurskie, 10-443, Poland
Tver', 125170, Russia
Pamplona/ Navarra, 31008, Spain
Chernihiv, 14029, Ukraine
Dnipropetrovsk, 49027, Ukraine
Kharkiv, 61018, Ukraine
Kharkiv, 61022, Ukraine
Kyiv, 03115, Ukraine
Odesa, 65009, Ukraine
Vinnytsia, 21005, Ukraine
Zaporizhya, 6972, Ukraine
Zaporizhzhya, 69035, Ukraine